After the GLP-1 Controversy: Why HIMS Still Stands Behind Its 2030 Vision

Following the release of $Hims & Hers Health (HIMS.US)$ Q4 2025 and full-year results, shares tumbled over 6% in pre-market trading. The market's logic was straightforward: while Q4 fundamentals weren't bad, investors chose to discount 2026's growth trajectory at a lower multiple—driven by concerns over weak near-term guidance and regulatory uncertainty surrounding GLP-1.

In the wake of the compounded GLP-1 policy turbulence, this earnings report has become a critical litmus test for HIMS's long-term value proposition. Despite management reaffirming ambitious 2030 targets—$6.5 billion in revenue and $1.3 billion in adjusted EBITDA—the "conservative" Q1 guidance struck a nerve with the market's most sensitive concern: visibility of growth.

The company projects Q1 2026 revenue of $600-625 million, representing just 2%-7% year-over-year growth—significantly below market expectations. Adjusted EBITDA guidance of $35-55 million (implying a ~7% margin at midpoint) was equally cautious.

Adding to the uncertainty, the FDA recently announced it would take action against non-FDA-approved GLP-1-related products being mass-marketed. This means that as long as regulatory variables remain in play, GLP-1 resembles more of a "volatility driver" than a "reliable growth engine."

Q4 Financial Breakdown: The Foundation Remains Solid

Setting aside stock price movements, Q4's operational metrics actually delivered several bright spots:

- Revenue and User Quality Both Advancing: Q4 revenue reached $618 million (up 28% YoY), with subscribers surpassing 2.5 million (up 13% YoY). More notably, Average Revenue Per User (ARPU) climbed to $83 (up 28% YoY and higher than Q3's $80). This indicates growth isn't merely driven by new user acquisition, but by deeper engagement and longer retention—a core validation of platform stickiness.

- Profitability Continues to Materialize: Q4 GAAP net income hit $21 million, with adjusted EBITDA at $66 million; full-year adjusted EBITDA reached $318 million, up 80% YoY. These profit figures demonstrate that the business model is proven and possesses scalable profitability potential.

- International Operations Emerge as New Growth Pole: International revenue reached $134 million, skyrocketing 399% YoY. While still a small base, the growth rate is eye-catching and lays groundwork for future global expansion.

Hidden Concerns and Signals Behind the Data

1. Why Is Gross Margin Compressing?

Q4 gross margin fell to 72%, down 500 basis points YoY. On the surface, this appears to erode profitability, but upon closer examination: the primary headwinds include rising international mix, startup costs for new offerings (Labs, hormone therapy), and structural changes in weight management product delivery frequency. Meanwhile, scale effects in non-weight-loss categories are offsetting some pressure. Thus, margin compression signals "tactical investment" rather than "model deterioration."

2. Marketing Efficiency Actually Improving

Marketing spend as a percentage of revenue dropped from 46% to 39%—a positive signal. Management noted that while the long-term target for customer acquisition payback remains under 12 months, recent years have tracked closer to 6-7 months. This suggests strengthening brand awareness and repeat purchase behavior—achieving the same growth at lower cost.

3. Why Does Cash Flow Look "Ugly"?

Q4 operating cash flow was $61 million, but free cash flow turned negative at -$3 million. While this appears concerning on the surface, it's actually the result of strategic capital intensification: CapEx increased significantly, primarily for pharmacy automation facilities and sterile injectables capacity. The company ended the quarter with $929 million in liquidity—plenty of firepower. For the full year, operating cash flow reached $300 million and free cash flow exceeded $57 million, proving the core business's cash generation remains intact.

How Does the Growth Narrative Continue Amid Regulatory Headwinds?

The market's real anxiety isn't about past profits, but whether the company can sustain high-quality growth through 2026's regulatory fog. Management provided full-year guidance: $2.7-2.9 billion in revenue (15%-24% growth) with 11%-13% adjusted EBITDA margins. They simultaneously reaffirmed 2030 targets: revenue ≥$6.5 billion and adjusted EBITDA ≥$1.3 billion.

Here's an unavoidable reality: GLP-1-related products contributed nearly $700 million in revenue in 2025. As the regulatory landscape shifts, Hims must lean on non-weight-loss offerings (hair loss, skincare, mental health—the core foundation) to fill this gap and drive incremental growth.

So where does this confidence come from?

The answer likely lies in the company's deep understanding of the "subscription healthcare" moat. Much like Netflix transformed entertainment consumption, Hims is reshaping how younger generations access care through its "telemedicine + personalized medications" closed loop. Once this high-retention model achieves scale, it genuinely possesses flywheel potential.

Q4 data validates this thesis: whether from organic brand traffic or acquired users, customer acquisition efficiency remains strong. More importantly, the double-digit adjusted EBITDA margin guidance signals management's continued confidence in the underlying business's earning power.

Globalization: The Underappreciated Second Growth Curve

During the earnings call, international expansion was explicitly identified as one of the most important investment priorities for the coming years. Notably, 2026 guidance does not yet include contributions from the recently announced Eucalyptus acquisition.

This Australian digital health platform currently generates over $450 million in annual recurring revenue in international markets. At the current trajectory, Eucalyptus could contribute over $1 billion in annual revenue to HIMS within three years. This means achieving the 2030 target doesn't hinge on "compounded GLP-1 selling indefinitely," but rather on three growth engines working in relay: platform capabilities + category expansion + internationalization.

Key Variables for Investors to Watch in 2026

1. GLP-1 Compliance and Supply Rules: The FDA's enforcement pace and positioning will determine the "certainty premium" for the weight management business.

2. Can Non-GLP New Verticals Scale to $100M+: Whether Labs, low testosterone, menopause support, etc., can become "secondary growth engines."

3. International M&A Integration and Returns Path: Eucalyptus synergies, customer acquisition efficiency, and execution on "scale first, profit later."

4. Profitability Quality—Marketing Payback and Margin Recovery: While marketing efficiency has improved, whether structural pressures on gross margin can ease will determine if valuation multiples can re-expand.

Conclusion

Hims & Hers stands at a crossroads: on one side, near-term uncertainty from regulatory risks; on the other, a compelling long-term growth narrative. Q4 data demonstrates that the company's vertically integrated platform has proven its resilience outside the traditional healthcare system. If it can successfully navigate the current GLP-1 regulatory cycle and replicate prior success in new business areas, the $6.5 billion revenue target for 2030 may well be within reach.

61K Views